Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01595620 · ClinicalTrials.gov registry record · Early Phase 1
Cannabinoid Modulation of Pain
A Early Phase 1 study, sponsored by Yale University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 6
- Enrollment target
NCT01595620: Completed Early Phase 1 study, sponsored by Yale University.
NCT01595620 is a Early Phase 1 study that has completed, run by Yale University. The registered enrollment target is 6 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (89% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01595620, a Early Phase 1 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
The purpose of this study is to test the effects of cannabinoids on pain response using a variety of human experimental pain models.
Interventions
- DRUG THC
- OTHER Electrical
- OTHER Thermal
- OTHER Capsaicin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2011-11-09 |
| Est. Completion | 2012-04-19 |
| Phase | Early Phase 1 |
What the finished NCT01595620 record still lists
NCT01595620 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (89% lower).
The record links to 0 conditions, and to 4 interventions - of which THC is the first listed.
NCT01595620 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01595620 about?
NCT01595620 is a clinical study titled "Cannabinoid Modulation of Pain". The purpose of this study is to test the effects of cannabinoids on pain response using a variety of human experimental pain models.
What is the current status of trial NCT01595620?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 6 participants. The study started on 2011-11-09. Estimated completion is 2012-04-19.
What interventions are being tested in trial NCT01595620?
The interventions under investigation include: THC (DRUG), Electrical (OTHER), Thermal (OTHER), Capsaicin (OTHER).
Who is sponsoring clinical trial NCT01595620?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01595620's enrollment target sits among peer trials
6 1846th of 2000 higher than 114 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI